The purpose of the study was to study the level of insulin-like growth factor-1 in the blood of patients with coronary heart disease with type 2 diabetes mellitus, in patients with coronary heart disease without type 2 diabetes mellitus and in almost healthy individuals. Materials and methods. We examined 73 patients (30 men, 43 women) with coronary heart disease aged 49 to 75 years (mean age –58.3 ± 1.8). All patients were treated in the therapeutic department of the prof. А. А. Shalimov Kharkiv Municipal Clinical Hospital No. 2. Examination of patients was performed using clinical, laboratory and instrumental methods. All patients had ischemic heart disease in the form of stable angina pectoris of I – II functional classes, I functional class was diagnosed in 27 patients, II – in 46 patients. From the group of examined patients in 36 patients the disease was accompanied by concomitant type 2 diabetes mellitus (group 1). Mild diabetes was detected in 15 people, moderate – in 21 patients. 37 patients did not have diabetes mellitus (group 2). Diagnosis of diabetes was based on the criteria of the World Diabetes Federation. The control group consisted of 20 people of the same age, who according to the results of clinical and additional studies were found to be practically healthy. Determination of insulin-like growth factor-1 and insulin levels in the blood was performed by enzyme-linked immunosorbent assay on a «Humareader photometer-analyzer». DRG kits (USA) were used to study the level of insulin-like growth factor-1. Results and discussion. It was found that patients with coronary heart disease with concomitant type 2 diabetes had higher levels in serum triglycerides (p <0.05) and very low density lipoprotein cholesterol (p <0.05) compared with patients with coronary heart disease without diabetes. Patients with coronary heart disease and concomitant type 2 diabetes showed a statistically significant increase in blood insulin levels compared with patients with coronary heart disease without diabetes. The results of the analysis of insulin-like growth factor-1 showed that the content of insulin-like growth factor-1 in the blood of patients with coronary heart disease and type 2 diabetes was probably lower compared with patients with coronary heart disease without diabetes and with practically healthy individuals (p <0.01). At the same time, the levels of insulin-like growth factor-1 in almost healthy individuals and patients with coronary heart disease without type 2 diabetes did not differ significantly. Conclusion. In patients with coronary heart disease with type 2 diabetes the level of insulin-like growth factor-1 is probably lower than in patients with coronary heart disease without diabetes and almost healthy individuals. Given the antiapoptotic, antiatherosclerotic, anabolic properties of this growth factor, it can be argued that the development of relative insulin-like growth factor-1 deficiency in the combination of coronary heart disease with type 2 diabetes causes a significant increase in the risk of cardiovascular complications in this category of patients

Keywords: insulin-like growth factor-1, indicators of lipid metabolism, coronary heart disease, type 2 diabetes mellitus

Full text: PDF (Eng) 261K

1. Nesen AO, Hrunchenko MM, Shkapo VL, Valentynova IA, Chyrva OV. Sertsevo-sudynnyi ryzyk ta komorbidnist — hostri problemy pohirshannya stanu zdorov’ya suspilstva [Cardiovascular risk and comorbidity are acute problems of deteriorating public health]. ScienceRise. 2015:1(3):41-48. [Ukrainian]. https://doi.org/10.15587/2313-8416.2015.36749
2. Dolzhenko MM, Perepelchenko NA, Bazylevych AYa. Ishemichna khvoroba sertsya na tli tsukrovoho diabetu typu 2: osoblyvosti perebihu ta obhruntuvannya terapiyi: monohrafiya [Ischemic heart disease on the background of type 2 diabetes mellitus: features of the course and rationale for therapy: a monograph]. K: Medknyha; 2010. 100 s. [Ukrainian]
3. Bentsa TM. Osobennosti techeniya ishemicheskoy bolezni serdtsa u bolnykh sakharnym diabetom 2-go tipa [Features of the course of coronary heart disease in patients with type 2 diabetes mellitus]. Liki Ukrayini. 2017;2:10-4. [Russian]
4. Rudenko AV, Mitchenko OI, Hutovskyi VV. Ishemichna khvoroba sertsya u patsiyentiv iz tsukrovym diabetom: monohrafiya [Ischemic heart disease in patients with diabetes mellitus: a monograph]. Zah red AV Rudenk, OI Mitchenko. K: Ahat-Prynt; 2016. 181 s. [Ukrainian]
5. Koval SM, Yushko KO. Tsukrovyi diabet 2-ho typu ta sertsevo-sudynni zakhvoryuvannya Chastyna I. Vyznachennya problemy, stratyfikatsiya kardiovaskulyarnoho ryzyku i osnovni napryamky profilaktyky sertsevo-sudynnykh zakhvoryuvan u khvorykh na tsukrovyi diabet 2-ho typu [Type 2 diabetes mellitus and cardiovascular diseases Part I. Problem definition, cardiovascular risk stratification and main directions of cardiovascular disease prevention in patients with type 2 diabetes mellitus]. Arteryalnaya hypertenzyya. 2020;13(5):39–47. [Ukrainian]
6. Lytvynova OM, Yeromenko RF, Lytvynenko HL. Metabolichni porushennya u khvorykh na ishemichnu khvorobu sertsya, poyednanu z tsukrovym diabetom 2 typu [Metabolic disorders in patients with coronary heart disease associated with type 2 diabetes]. Aktualnye nauchnye yssledovanyya v sovremennom myre. 2017;10(30);112-116. [Ukrainian]
7. Ametov AS. Sakharnyy diabet 2 tipa [Type 2 diabetes mellitus]. Problemy i resheniya. 2-e izd, pererab i dop. M: GEOTAR-Media; 2014. 1032 s. [Russian]
8. Mankovskiy BN. Aktualnye voprosy profilaktiki i lecheniya serdechno-sosudistykh zabolevaniy u bolnykh sakharnym diabetom [Topical issues of prevention and treatment of cardiovascular diseases in patients with diabetes mellitus]. Mistetstvo likuvannya. 2003;1:21–25. [Russian]
9. Svintsitskyi I. Osoblyvosti urazhennya vintsevoho rusla u khvorykh na stabilnu ishemichnu khvorobu sertsya iz tsukrovym diabetom 2-ho typu: odnotsentrove kros-sektsiyne doslidzhennya [Features of coronary artery disease in patients with stable coronary heart disease with type 2 diabetes mellitus: one-center cross-sectional study]. Endocrinology. 2017;22(3):245-250. [Ukrainian]
10. Koval SM, Snihurska IO, Penkova MYu, Litvinova OM, Bozhko VV, Yushko KO. Arterialna hipertenziya ta tsukrovyi diabet: pytannya optymizatsiyi kontrolyu arterialnoho tysku [Hypertension and diabetes mellitus: issues of optimizing blood pressure control]. Arteryalnaya hypertenziya. 2018;2(58):9-18. [Ukrainian]. https://doi.org/10.22141/2224-1485.2.58.2018.131061
11. Pankiv VI. Tsukrovyi diabet, pereddiabet i sertsevo-sudynni zakhvoryuvannya [Diabetes, pre-diabetes and cardiovascular diseases]. Praktychna anhiolohiya. 2017;1(6):4-10. [Ukrainian]
12. Koval SM, Yushko KO, Snihurska IO, Starchenko TG, Lytvynova OM. Relations of angiotensin-(1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial hypertension. 2019;23(3):183–189. https://doi.org/10.5603/AH.a2019.0012
13. Delafontaine P, Song YH, Li Y. Expression, Regulation, and Function of IGF–1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):435-44. PMID: 14604834. https://doi.org/10.1161/01.ATV.0000105902.89459.09
14. Bailey-Downs LC, Sosnowska D, Toth P, Mitschelen M, Gautam T, Henthorn JC, et al. Growth hormone and IGF-1 deficiency exacerbate high-fat diet-induced endothelial impairment in obese Lewis dwarf rats: implications for vascular aging. J Gerontol A Biol Sci Med Sci. 2012 Jun;67(6):553-64. PMID: 22080499. PMCID: PMC3348491. https://doi.org/10.1093/gerona/glr197
15. Jones JI, Clemmons DR. Insulin-like factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3-34. PMID: 7758431. https://doi.org/10.1210/edrv-16-1-3
16. Lapikova-Bryhinska TYu. Rol insulinopodibnoho faktora rostu 1 (IGF-1) u molekulyarno-henetychnykh mekhanizmakh rozvytku hipertrofiyi miokarda [The role of insulin-like growth factor 1 (IGF-1) in the molecular genetic mechanisms of myocardial hypertrophy]. Abstr. PhDr. (Biol.). К; 2020. 148 с. [Ukrainian]
17. Mitrushkin DI, Kubyshkin VF, Ushakov AV. Sistema insulinopodobnogo faktora rosta pri razlichnykh variantakh techeniya ishemicheskoy bolezni serdtsa [The system of insulin-like growth factor in various variants of the course of coronary heart disease]. Ukrayinskiy kardiologichniy zhurnal. 2007;6:32–37. [Russian]
18. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41(2):425–443. PMID: 22682639. PMCID: PMC3374394. https://doi.org/10.1016/j.ecl.2012.04.017
19. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol. 2008;159(4):389–397. PMID: 18603571. https://doi.org/10.1530/EJE-08-0201
20. Mizhnarodna Diabetychna Federatsiya (IDF) [International Diabetes Federation (IDF)]. [Ukrainian]. Available from: http://www.idf.org.
21. Lawlor DA, Ebrahim S, Smith GD, Cherry L, Watt P, Sattar N. The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women's Heart and Health Study. Atherosclerosis. 2008 Nov;201(1):198-204. PMID: 18295769. https://doi.org/10.1016/j.atherosclerosis.2007.12.061
22. Larsson SC, Michaëlsson K, Burgess S. IGF-1 and cardiometabolic diseases: a Mendelian randomisation study. Diabetologia. 2020 Sep;63(9):1775-1782. PMID: 32548700. PMCID: PMC7406523. https://doi.org/10.1007/s00125-020-05190-9
23. Higashi Y, Sukhanov S, Anwar A, et al. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci. 2012;67:626–639. PMID: 22491965. PMCID: PMC3348497. https://doi.org/10.1093/gerona/gls102
24. Burchardt P, Gozdzicka-Jozefiak A, Zurawski J, Nowak W, Durzynska J, Link R, et al. Are elevated levels of IGF-1 caused by coronary arteriesoclerosis? Molecular and clinical analysis. Protein J. 2010;29:538–544. PMID: 21046444. PMCID: PMC2992669. https://doi.org/10.1007/s10930-010-9288-7
25. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL. Insulin-like growth factors and coronary heart disease. Cardiol Rev. 2005;13:35–39. PMID: 15596027. https://doi.org/10.1097/01.crd.0000134914.10407.40
26. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939–949. PMID: 12186797. https://doi.org/10.1161/01.CIR.0000027563.44593.CC
27. Rehman U. The role of growth hormone in the pathogenesis of vascular complications of diabetes mellitus. Am J Med Sci. 2000;320:128–134.
28. Miyake H, Kanazawa I, Sugimoto T. Decreased serum insulin-like growth factor-I level is associated with the increased mortality in type 2 diabetes mellitus. Endocr J. 2016;63:811–8. PMID: 27349183. https://doi.org/10.1507/endocrj.EJ16-0076
29. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:2684–2690. PMID: 17916769. https://doi.org/10.1161/ATVBAHA.107.156257
30. Ryeznik LA, Koval SM, Vovchenko MM. Insulinopodibnyi faktor rostu 1 ta sertsevo-sudynni zakhvoryuvannya [Insulin-like growth factor 1 and cardiovascular disease]. [Ukrainian]. Available from: http://urgent.com.ua/article/499.html
31. Aguirre GA, Rodríguez De Ita J, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Translational Med. 2016;14(3):910–918.